Site Search
Professionals 384 results
Capabilities 69 results
Practice Area
Winston is a leading advisor to public and private companies and investment advisers on corporate transactions. We have experience representing public and private companies, financial sponsors, boards of directors and special committees, financial advisors, and management teams. This perspective enables us to understand the concerns of parties on all sides of the table, protect our clients’ interests, and execute deals.
Practice Area
Securities, M&A & Corporate Governance Litigation
In today’s market, litigators with experience in securities, corporate governance, and M&A-related (collectively, “securities litigation”) matters need to leverage their broad experience to serve as both advocate and as counsel and strategist, focused on helping clients to overcome not just a legal issue but a collective business problem. Given the frequent interplay between things such as corporate-control transactions, public offerings, activist shareholders, the use of complex derivatives and other financial instruments, bad news impacting stock performance, regulatory inquiries and investigations, and insurance coverage, strategic and tactical litigation decisions can have a wide-ranging impact on the success of a given transaction, as well as on companies, their boards, senior management, and advisors.
Experience 177 results
Experience
|September 9, 2025
Winston & Strawn LLP represented Greenland Exploration Limited in a landmark business combination with Pelican Acquisition Corporation (NASDAQ: PELI) and March GL Company. The transaction, structured as a merger agreement, will result in the formation of Greenland Energy Company, expected to be publicly listed on NASDAQ under the ticker symbol “GLND.” Winston advised Greenland Exploration on all aspects of the deal, including regulatory strategy, corporate structuring, and negotiation of the merger terms.
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.
Experience
|March 18, 2025
Winston Blunts Earnout Payment
Following a bench trial in Fall 2024, a New York trial court ruled in March 2025 that Cresco Labs, Inc. was not required to pay a US$45M earnout under a merger agreement. The court found that Cresco did not receive “commercially reasonable access” to New York’s adult-use cannabis market, which was supposed to be subject only to a non-competitive application or approval process. Adopting Cresco’s arguments, the court determined that only the Office of Cannabis Management and Cannabis Control Board could decide when and how applicants access the adult-use market. The court agreed that regulators required Cresco to pay a significant one-time fee, prioritized other applicants, and had broad discretion over approvals. This win supports claims that New York’s adult-use program lacks details and clear entry paths, frustrating industry leaders’ efforts to develop a robust adult-use market.
Insights & News 1,104 results
Competition Corner
|September 30, 2025
|5 Min Read
Enforcement Priorities of the FTC and DOJ—Insights from Recent Antitrust Conferences
The landscape of antitrust enforcement in the United States continues to undergo a significant transformation, as highlighted by recent remarks from leaders at both the Federal Trade Commission and the Department of Justice.
Global Trade & Foreign Policy Insights
|September 30, 2025
|6 Min Read
The BIS 50 Percent Ownership Rule: A Paradigm Shift
Effective September 29, 2025, many thousands of additional non-U.S. entities around the world are now prohibited from receiving U.S. goods, software, and technology under an “affiliates” interim final rule (the IFR) published by the Bureau of Industry and Security (BIS) at the U.S. Department of Commerce.
Seminar/CLE
|September 18, 2025
Winston Hosts New York Financial Services Symposium 2025
Winston’s Financial Services Industry Group was pleased to host our New York Financial Services Symposium. The event included a half-day of programming led by top industry thought leaders. Find key takeaways from each panel discussion below.
Other Results 26 results
Site Content
“Baby HSR” or “mini HSR” laws refer to state-level premerger notification and reporting requirements that resemble the federal Hart-Scott-Rodino Act but tend to apply to smaller transactions valued below the federal notification thresholds. These laws, often focused on specific industries like healthcare, aim to enhance state-level antitrust oversight by requiring companies to notify state authorities of mergers or acquisitions that could impact local competition. Filing obligations, timing, and fees vary by state, with some requiring detailed disclosures about the transaction’s competitive impact within the state. State authorities can investigate, challenge, or impose conditions on transactions even if they are cleared federally. Winston’s Baby HSR survey provides buyers and sellers with a resource to quickly start assessing which states may have premerger notification requirements that impact their transactions.
Location
Winston & Strawn’s Brussels office further establishes our preeminent EU antitrust/competition practice at the epicenter of European competition law. The office is located on the famous Rue de la Loi or Wetstraat, which connects the Belgium Federal Parliament with the European Commission headquarters—the Berlaymont—and the Justus Lipsius, home to the Council of the European Union.